| Literature DB >> 28336457 |
Jing Li1, Jun Zhang1, Yiyue Wang1, Xiao Liang1, Zaitongguli Wusiman1, Yunzhi Yin1, Qi Shen2.
Abstract
Metastasis impedes the successful chemotherapy for breast cancer. In this study, an Akt inhibitor (quercetin, Qu) was co-delivered with a chemotherapeutic agent (docetaxel, DTX) by using hyaluronic acid (HA)-modified nanoparticles (NPs) as vectors to block metastasis. Dual DTX/Qu-loaded HA/polylactic-co-glycolic acid-polyethyleneimine NPs (PP-HA/NPs) were prepared through a modified emulsion solvent evaporation technique. The particle size of PP-HA/NPs with narrow polydispersity was 209.8±10.8nm. Wound healing assay revealed that Qu co-delivery and HA modification elicited synergistic inhibitory effects on cell motility. The downregulation of p-Akt and matrix metalloproteinase-9 (MMP-9) expression contributed to the significant inhibition of cell migration and invasion with inhibition rates of 95.6% and 99.3%, respectively. Further studies indicated that PP-HA/NPs could be efficiently uptaken by 4T1 breast cancer cells and could further induce cytotoxicity, decrease colony formation and promote cell apoptosis. Biodistribution assay demonstrated PP-HA/NPs also enhanced drug accumulation in the tumor and lungs and predicted that PP-HA/NPs could be employed as an effective therapy for primary tumor and pulmonary metastasis. Therefore, PP-HA/NPs could be a promising delivery system to treat metastatic breast cancer effectively.Entities:
Keywords: Akt/MMP-9 pathway; Breast cancer; Hyaluronic acid; Metastasis docetaxel; Quercetin
Mesh:
Substances:
Year: 2017 PMID: 28336457 DOI: 10.1016/j.ijpharm.2017.03.040
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875